跳至主要内容
临床试验/NL-OMON56079
NL-OMON56079招募中不适用

Glymphatic dysfunction in cognitive impairment: a memory clinic study - GlyM

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients with Alzheimer's disease (AD) dementia:
  • -Diagnosis of dementia of the AD type (McKhann et al. 2011)
  • -Age > 55 years
  • -Mentally competent (MMSE>=18) and able to give informed consent
  • -Informed consent before participation in the study
  • Patients with Mild cognitive impairments (MCI) or Subjective cognitive
  • impairment (SCI):
  • -Diagnosis of MCI (Albert et al. 2011) or diagnosis of Mild Neurocognitive
  • Disorder (DSM V) (Sachs-Ericsson and Blazer 2015) or diagnosis of SCI as given
  • by the memory clinic (SCI is defined by an individual experiencing subjective
  • complaints and visiting the memory clinic for these complaints, but not showing
  • a significant decline in objective cognitive assessment)
  • -Age > 55 years
  • -Mentally component (MMSE >=18) and able to give informed consent
  • -Informed consent before participation in the study
  • Control subjects:
  • -Mini-Mental State Examination (MMSE) >= 26
  • -Age > 55 years
  • -Mentally component (MMSE >=18) and able to give informed consent
  • -Informed consent before participation in the study

排除标准

  • - Any significant disease or unstable medical condition that could influence
  • neuropsychological testing (with the exception of a SCI, MCI or AD diagnosis)
  • - Major depression (according to the DSM IV) (< 12 months ago)
  • - Psychiatric history (schizophrenia, schizoaffective disorder, bipolar
  • disorder or any his-tory of electroconvulsive therapy)
  • - Vascular dementia
  • - Ischemic or valvular heart disease or electrocardiographic evidence of atrial
  • fibrillation
  • - Recent transient ischemic attacks and ischemic or haemorrhagic stroke or
  • cerebrovascular accident (< 2 years or paired with cognitive decline within 3
  • months after incident)
  • - Obstructive sleep apnoea syndrome
  • - Normal Pressure Hydrocephalus, M. Huntington, Parkinson*s disease,
  • Frontotemporal dementia, Motor neuron diseases, Multiple sclerosis, Epilepsy
  • - Systemic inflammation, such as active rheumatoid arthritis
  • - Diabetes
  • - Cognitive impairment due to alcohol/drug abuse
  • - Structural abnormalities of the brain, such as tumours or stroke lesions
  • - Inability to provide informed consent
  • - Any contraindication for MRI: metallic implants, pacemaker, claustrophobia,
  • pregnancy, tattoos in the head/neck region (with potential exception of
  • make-up after assessment with SOP permanent make-up)
  • - Unwillingness to be informed about potential abnormal MRI-findings

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验